JNJ

225.07

-1.1%↓

ABT

92.85

+1.8%↑

MDT

82.92

-0.55%↓

A

115.57

+0.14%↑

VEEV

160.16

-0.42%↓

JNJ

225.07

-1.1%↓

ABT

92.85

+1.8%↑

MDT

82.92

-0.55%↓

A

115.57

+0.14%↑

VEEV

160.16

-0.42%↓

JNJ

225.07

-1.1%↓

ABT

92.85

+1.8%↑

MDT

82.92

-0.55%↓

A

115.57

+0.14%↑

VEEV

160.16

-0.42%↓

JNJ

225.07

-1.1%↓

ABT

92.85

+1.8%↑

MDT

82.92

-0.55%↓

A

115.57

+0.14%↑

VEEV

160.16

-0.42%↓

JNJ

225.07

-1.1%↓

ABT

92.85

+1.8%↑

MDT

82.92

-0.55%↓

A

115.57

+0.14%↑

VEEV

160.16

-0.42%↓

Search

ResMed Inc

Gesloten

SectorGezondheidszorg

222.12 1.1

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

219.17

Max

223.9

Belangrijke statistieken

By Trading Economics

Inkomsten

44M

393M

Verkoop

87M

1.4B

K/W

Sectorgemiddelde

22.368

60.328

Dividendrendement

0.99

Winstmarge

27.593

Werknemers

10,600

EBITDA

63M

566M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+29.86% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

0.99%

2.24%

Volgende Winsten

30 apr 2026

Volgende dividenddatum

11 jun 2026

Volgende Ex Dividend datum

7 mei 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-4.3B

33B

Vorige openingsprijs

221.02

Vorige sluitingsprijs

222.12

Nieuwssentiment

By Acuity

10%

90%

12 / 348 Rangschikking in Healthcare

ResMed Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

27 apr 2026, 23:15 UTC

Belangrijke Nieuwsgebeurtenissen

U.K. Consumers Pay Less But Full Impact of Mideast War to Be Seen

27 apr 2026, 23:08 UTC

Winsten
Belangrijke Marktbewegers

LendingClub Shares Gain on 1Q Profit, Revenue Beat

27 apr 2026, 23:58 UTC

Winsten

Samsung SDI 1Q Net Profit Beat FactSet-Compiled Consensus

27 apr 2026, 23:58 UTC

Winsten

Samsung SDI 1Q Net KRW56.10B Vs. Loss KRW216.00B >006400.SE

27 apr 2026, 23:56 UTC

Winsten

Samsung SDI 1Q Oper Loss KRW155.60B Vs. Loss KRW434.10B >006400.SE

27 apr 2026, 23:56 UTC

Winsten

Samsung SDI 1Q Rev KRW3.576T Vs. KRW3.177T >006400.SE

27 apr 2026, 23:48 UTC

Marktinformatie

Nikkei May Remain Rangebound Amid Uncertainty Over Iran Conflict -- Market Talk

27 apr 2026, 23:42 UTC

Marktinformatie

Australian Consumer Confidence Making a Slow Come Back -- Market Talk

27 apr 2026, 23:34 UTC

Marktinformatie
Belangrijke Nieuwsgebeurtenissen

Gold Edges Higher as Investors Assess Iran's Proposal to U.S. -- Market Talk

27 apr 2026, 23:30 UTC

Marktinformatie

Australia's NDIS Could Lose 'Social Licence' If Not Reined In -- Market Talk

27 apr 2026, 23:08 UTC

Marktinformatie

Polymetals's Revenue Outlook 'Extraordinary' for a Small-Cap Stock -- Market Talk

27 apr 2026, 23:02 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

27 apr 2026, 23:02 UTC

Marktinformatie

Warsh Will Probably Lean a Bit More Dovish Than Powell -- Market Talk

27 apr 2026, 22:42 UTC

Marktinformatie

BOJ Expected to Keep Rates On Hold; Guidance to Skew Hawkish -- Market Talk

27 apr 2026, 22:10 UTC

Winsten

Haier Smart Home: Results Also Weighed by Weak Demand in China-U.S. Markets >600690.SH

27 apr 2026, 22:09 UTC

Winsten

Haier Smart Home: Increase in Tariff Costs, Extreme Weather Conditions Hurt Results >600690.SH

27 apr 2026, 22:09 UTC

Winsten

Haier Smart Home 1Q Net CNY4.65B Vs. Net CNY5.49B >600690.SH

27 apr 2026, 22:09 UTC

Winsten

Haier Smart Home 1Q Rev CNY73.69B Vs. CNY79.12B >600690.SH

27 apr 2026, 21:56 UTC

Winsten

Tsingtao Brewery: Cost Controls Among Factors Supporting Results >0168.HK

27 apr 2026, 21:55 UTC

Winsten

Tsingtao Brewery 1Q Net CNY1.80B Vs. Net CNY1.71B >0168.HK

27 apr 2026, 21:55 UTC

Winsten

Tsingtao Brewery 1Q Rev CNY10.29B Vs. CNY10.45B >0168.HK

27 apr 2026, 21:44 UTC

Winsten

Tianqi Lithium: Higher Demand for Products From EV Sector Also Boosted Financial Performance >002466.SZ

27 apr 2026, 21:43 UTC

Winsten

Tianqi Lithium: Increase in Average Selling Prices of Major Lithium Products Supported Results >002466.SZ

27 apr 2026, 21:41 UTC

Winsten

Tianqi Lithium 1Q Rev CNY5.13B Vs. CNY2.58B >002466.SZ

27 apr 2026, 21:41 UTC

Winsten

Tianqi Lithium 1Q Net CNY1.88B Vs. Net CNY104.27M >002466.SZ

27 apr 2026, 20:50 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

27 apr 2026, 20:50 UTC

Marktinformatie
Belangrijke Nieuwsgebeurtenissen

Basic Materials Roundup: Market Talk

27 apr 2026, 20:50 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Financial Services Roundup: Market Talk

27 apr 2026, 20:50 UTC

Marktinformatie

Health Care Roundup: Market Talk

27 apr 2026, 20:39 UTC

Winsten

Nucor: Operating Segments Earnings Growth Driven by Trade Policies That Continue to Reduce Flood of Unfairly Traded Imports Into U.S. >NUE

Peer Vergelijking

Prijswijziging

ResMed Inc Prognose

Koersdoel

By TipRanks

29.86% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 285.5 USD  29.86%

Hoogste 340 USD

Laagste 255 USD

Gebaseerd op 13 Wall Street-analisten die 12-maands prijsdoelen bieden voor ResMed Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

13 ratings

8

Buy

5

Hold

0

Sell

Sentiment

By Acuity

12 / 348 Rangschikking in Gezondheidszorg

Nieuwssentiment

Zeer Sterk Bearish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over ResMed Inc

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME) to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies; and MEDIFOX DAN's software solutions. The company markets its products to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
help-icon Live chat